Tuesday’s Highlights at Noon: American Green Inc (ERBB), Rosetta Genomics Ltd (ROSG), Conatus Pharmaceuticals (CNAT), OncoSec Medical (ONCS), ImmunoCellular Therapeutics (IMUC)

By Carrie Williams

So far Tuesday, January 29, NASDAQ is down -1.77% and the S&P is down -0.11%. Here are this morning’s most active stocks: American Green Inc (ERBBResearch Report), Rosetta Genomics Ltd (ROSGResearch Report), Conatus Pharmaceuticals (CNATResearch Report), OncoSec Medical (ONCSResearch Report) and ImmunoCellular Therapeutics (IMUCResearch Report).

American Green Inc is up 33.33% in midday trading to $0.00. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00.

Rosetta Genomics Ltd is up 25% in midday trading to $0.01. Shares opened today at $0.01. The company has a 52-week low of $0.00 and a 52-week high of $0.00.

Conatus Pharmaceuticals is up 18.64% in midday trading to $2.10. Shares opened today at $1.77. The company has a 52-week low of $1.15 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $9.33, marking a 427.12% potential upside from current levels. In a report issued on December 6, Stifel Nicolaus analyst Stephen Willey downgraded CNAT to Hold, with a price target of $4, which implies an upside of 126% from current levels. Separately, on the same day, H.C. Wainwright’s Ed Arce maintained a Buy rating on the stock and has a price target of $14.

See today’s analyst top recommended stocks >>

OncoSec Medical is up 8.94% in midday trading to $0.82. Shares opened today at $0.76. The company has a 52-week low of $0.54 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $3.00, marking a 296.30% potential upside from current levels. In a report issued on January 7, Maxim Group analyst Jason McCarthy maintained a Buy rating on ONCS, with a price target of $5, which implies an upside of 561% from current levels. Separately, on November 7, H.C. Wainwright’s Ram Selvaraju downgraded the stock to Hold and has a price target of $1. In the last 30 days, insiders have sold $9,097 worth of ONCS shares. Over the last 3 months, the insider sentiment on OncoSec Medical has been positive based on 13 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

ImmunoCellular Therapeutics is up 8.7% in midday trading to $0.03. Shares opened today at $0.02. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Trending Stocks Based on Insider Activity >>